Tesamorelin
One of the few here that is an actual approved medicine — for a specific condition that is not hypermobility.
FDA approved medicine
| What it is | A growth hormone releasing factor analogue, approved and marketed as Egrifta. |
|---|---|
| How it is thought to work | Stimulates pituitary growth hormone release, reducing visceral fat. |
| What the evidence actually shows | Approved on the strength of randomised controlled trials in HIV-associated lipodystrophy, where it reduced visceral adipose tissue. |
| Regulatory status | FDA approved as Egrifta, for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general body composition, anti-ageing, or connective tissue purposes. |
| Dosing | The approved product's label specifies 2 mg by subcutaneous injection once daily. That is the dose for the approved medicine, prescribed and monitored by a doctor for the approved indication — it is not guidance for research-grade material used for something else. |
| In the catalog as |
Risks and cautions
- Raises IGF-1; the label carries warnings around malignancy risk.
- Can worsen glucose tolerance.
- Injection site reactions are common.
- Prohibited in sport by WADA.
Before you act on any of this
This page describes what is known and what is not. It is not a recommendation to use anything, and it is not a protocol. Compounds listed as research chemicals are not approved medicines and are not sold for human use. Talk to a doctor who knows your history.